Roche Pharma seeking EUA from India for its COVID-19 antibody cocktail
Category: #headlines |   By Pankaj Singh |   Date: 2021-04-30

Roche Pharma seeking EUA from India for its COVID-19 antibody cocktail

Swiss multinational drug marker Roche Pharma recently announced that it is working with the Indian drug regulator to fast-track an emergency use authorization (EUA) of its investigational antibody cocktail Imdevimab and Casirivimab in India.

It is worth noting here that Roche Pharma has applied for a similar approval in the European Union and the United States. Roche claims that an emergency use authorization in India would allow the import of globally manufactured drugs to India as soon as possible.

The company added that is working promptly to expand manufacturing capacity and supply by upscaling its production network and building ties with external partners to maximize production of Tocilizumab (Actemra) at all possible site to increase its availability.

Roche cited that there is a magnified demand for Tocilizumab as the Covid-19 cases continue to surge across the nation. The company as a whole is addressing this grave situation by bringing in supplies over this and the coming weeks, however, worries that the current requirements may far surpass the supplies that will be provided, it added.

For the record, Tocilizumab is considered vital for patients who are moderately affected with Covid-19 and have rising oxygen requirements as time passes or in mechanically ventilated patients who aren’t showing any signs of improvements despite the utilization of steroids.

The drug, which is to be administered in two doses, is produced by Roche while Cipla looks after its and import and distribution in India. A few weeks earlier, this drug went out of stock in the nation due to its massive demand emerging from the steep incline of Covid-19 cases throughout April.

Given the growing necessity of minimizing hospitalization and relieving healthcare from the burgeoning pressure, neutralizing antibody cocktails can play a major role, particularly for the treatment of high-risk patients before their health condition worsens, cited the Swiss giant.

Source Credits –

https://www.moneycontrol.com/news/business/rbi-announces-special-omos-of-rs-10000-crore-each-on-may-6-6831851.html

 

  • shareShare
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh     Twitter

Pankaj Singh

With a commendable experience of content creation under his belt, Pankaj Singh, a qualified Post Graduate in Management, boasts of having worked as a freelance writer and an insurance underwriter. Additionally, Pankaj has also enriched his qualification portfolio with Read more...

More News By Pankaj Singh

Shaurrya Teleservices & Airwaive team up to expand 5G network in India

Shaurrya Teleservices & Airwaive team up to expand 5G network in India

By Pankaj Singh

Airwaive and Shaurrya Teleservices (STS) has reportedly announced an international strategic collaboration to jointly build 5G wireless network service in India, assisting telecom providers in advancing 5G technology throughout the nation. Notably...

Valneva looking to capitalize on growing prevalence of Lyme disease

Valneva looking to capitalize on growing prevalence of Lyme disease

By Pankaj Singh

French drugmaker Valneva SE is now reportedly betting on its vaccine VLA15 for treating climate change-induced Lyme disease, as it looks to capitalize on growing prevalence of tick-borne illnesses following the disappointing sales of its COVID-19 vac...

Reliance Jio becomes the largest buyer of India’s USD 19 Bn 5G sale

Reliance Jio becomes the largest buyer of India’s USD 19 Bn 5G sale

By Pankaj Singh

Reliance Jio Infocomm Ltd., owned by billionaire industrialist Mukesh Ambani, was found to be the most aggressive participant in the government-backed 5G auction in India where several telecom behemoths agreed to invest at least USD 19 billion. Jio w...